Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson's disease: a transcranial magnetic stimulation study

OBJECTIVES Transcranial magnetic stimulation was used to assess the effects of chronic levodopa and pergolide treatment on motor cortex excitability in Parkinson disease (PD). METHODS Motor thresholds, intracortical inhibition and facilitation were studied at baseline and after 6 and 12 months of therapy in 10 PD patients and compared to 7 age-matched controls. RESULTS At baseline, there was significantly less intracortical inhibition with only a slight reduction of intracortical facilitation in PD as compared to controls. Relative to pretreatment condition, levodopa restored intracortical inhibition for 12 months while pergolide did not. Intracortical facilitation was always within the normal range. Motor thresholds were unchanged in both groups of patients over 12 months. Clinically, levodopa and pergolide improved motor Unified Parkinson's disease rating scale (UPDRS) scores at 6 months but only levodopa maintained benefit at 12 months as compared to baseline. CONCLUSIONS Levodopa and pergolide differentially affected cortical inhibitory circuits at 12 months. The progressive deterioration of restored intracortical inhibition with pergolide may be due to the development of tolerance and down-regulation of dopamine receptors.

[1]  J. Rothwell,et al.  Changes in the balance between motor cortical excitation and inhibition in focal, task specific dystonia. , 1995, Journal of neurology, neurosurgery, and psychiatry.

[2]  B. G. Blijenberg,et al.  Spectrophotometric analysis of CSF after subarachnoid hemorrhage , 1983, Neurology.

[3]  T. Chase,et al.  Motor fluctuations in Parkinson's disease: Pathogenetic and therapeutic studies , 1987, Annals of neurology.

[4]  J. Bartko,et al.  Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II , 1988, Annals of neurology.

[5]  J. Rothwell,et al.  Interaction between intracortical inhibition and facilitation in human motor cortex. , 1996, The Journal of physiology.

[6]  A Rothenberger,et al.  Decreased motor inhibition in Tourette's disorder: evidence from transcranial magnetic stimulation. , 1997, The American journal of psychiatry.

[7]  F. Calon,et al.  Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex , 1995, Brain Research.

[8]  H. Tsuji,et al.  Intracortical facilitation and inhibition after transcranial magnetic stimulation in conscious humans. , 1997, The Journal of physiology.

[9]  R. Inzelberg,et al.  Changes in excitability of motor cortical circuitry in patients with parkinson's disease , 1995, Annals of neurology.

[10]  B. Steinhoff,et al.  Effects of antiepileptic drugs on motor cortex excitability in humans: A transcranial magnetic stimulation study , 1996, Annals of neurology.

[11]  R. Watts The role of dopamine agonists in early Parkinson's disease , 1997, Neurology.

[12]  J. Cedarbaum,et al.  Sustained‐release (+)‐PHNO [MK‐458 (HPMC)] in the treatment of Parkinson's disease: Evidence for tolerance to a selective D2‐receptor agonist administered as a long‐acting formulation , 1990, Movement Disorders.

[13]  C. Marsden,et al.  Receptor changes during chronic dopaminergic stimulation. , 1988, Journal of neural transmission. Supplementum.

[14]  Walter Paulus,et al.  Enhancement of human motor cortex inhibition by the dopamine receptor agonist pergolide: evidence from transcranial magnetic stimulation , 1996, Neuroscience Letters.

[15]  W Paulus,et al.  Changes in human motor cortex excitability induced by dopaminergic and anti-dopaminergic drugs. , 1997, Electroencephalography and clinical neurophysiology.

[16]  J. Jankovic Long‐term study of pergolide in Parkinson's disease , 1985, Neurology.

[17]  C. Marsden,et al.  Corticocortical inhibition in human motor cortex. , 1993, The Journal of physiology.

[18]  N Accornero,et al.  Motor cortical inhibition and the dopaminergic system. Pharmacological changes in the silent period after transcranial brain stimulation in normal subjects, patients with Parkinson's disease and drug-induced parkinsonism. , 1994, Brain : a journal of neurology.

[19]  M Hallett,et al.  Effects of phenytoin on cortical excitability in humans , 1997, Neurology.

[20]  Ichiro Kanazawa,et al.  Ipsilateral cortico-cortical inhibition of the motor cortex in various neurological disorders , 1996, Journal of the Neurological Sciences.